Leap Therapeutics Inc (LPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has a cash flow conversion efficiency ratio of -6.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.29 Million) by net assets ($2.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LPTX market cap for the company's overall valuation and market capitalisation.
Leap Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Leap Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Leap Therapeutics Inc ranked by their cash flow conversion efficiency. Explore LPTX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INNATE PHARMA SP.ADR/1
F:IDDA
|
N/A |
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
N/A |
|
Apiam Animal Health Ltd
AU:AHX
|
0.076x |
|
Singular People S.A.
MC:SNG
|
0.140x |
|
Rupa & Company Limited
NSE:RUPA
|
0.023x |
|
Endava plc
F:2Y5
|
0.050x |
|
Faze Three Limited
NSE:FAZE3Q
|
0.025x |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
0.174x |
Annual Cash Flow Conversion Efficiency for Leap Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Leap Therapeutics Inc from 2012 to 2024. View Leap Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.05 Million | $-60.30 Million | -1.720x | -136.49% |
| 2023-12-31 | $60.14 Million | $-43.75 Million | -0.728x | +18.95% |
| 2022-12-31 | $54.64 Million | $-49.04 Million | -0.898x | -175.43% |
| 2021-12-31 | $107.89 Million | $-35.16 Million | -0.326x | +15.38% |
| 2020-12-31 | $67.41 Million | $-25.96 Million | -0.385x | -102.50% |
| 2019-12-31 | $-1.75 Million | $-26.90 Million | 15.381x | +642.10% |
| 2018-12-31 | $9.18 Million | $-26.03 Million | -2.837x | -42.49% |
| 2017-12-31 | $11.12 Million | $-22.14 Million | -1.991x | -- |
| 2016-12-31 | $0.00 | $-25.34 Million | x | -- |
| 2015-12-31 | $26.87 Million | $-19.58 Million | -0.729x | -86.90% |
| 2014-12-31 | $46.21 Million | $-18.02 Million | -0.390x | +26.38% |
| 2013-12-31 | $18.77 Million | $-9.94 Million | -0.530x | +8.14% |
| 2012-12-31 | $13.10 Million | $-7.55 Million | -0.577x | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more